Opinion
Video
Author(s):
Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm
Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
Venetoclax/Rituximab Retreatment Produces Durable Responses in CLL
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Response-Based Intermittent Ibrutinib Dosing Shows Safety, Feasibility in CLL
utDNA Could Provide Noninvasive Tool for MRD Detection Prior to Repeat TURBT in High-Risk NMIBC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress